SCHEMBL6796512

SCHEMBL6796512

CCN(CC)c1ccc(/C=C2/N=C(c3ccc(C)cc3)OC2=O)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.58
ALDH1A1 P00352 5/20 0.57
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
NOTUM Q6P988 1/20 0.51
CSNK2A2 P19784 3/20 0.51
CSNK2B P67870 3/20 0.51
CSNK2A1 P68400 3/20 0.51
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 2/20 0.48
HPGD P15428 1/20 0.48
PLCG2 P16885 1/20 0.48
KDM4E B2RXH2 2/20 0.47
POLB P06746 1/20 0.47
TP53 P04637 1/20 0.46
F2 P00734 1/20 0.46
F10 P00742 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6796514 1.00 MAPK1 (0.58) MAPK1ALDH1A1NPC1RAB9ANOTUM
SCHEMBL6790249 0.90 PLCG2 (0.60) ALDH1A1NOTUMCSNK2A2CSNK2BCSNK2A1
SCHEMBL6790252 0.90 PLCG2 (0.60) ALDH1A1NOTUMCSNK2A2CSNK2BCSNK2A1
SCHEMBL6797901 0.89 ALDH1A1 (0.53) MAPK1ALDH1A1NPC1RAB9ANOTUM
SCHEMBL6797903 0.89 ALDH1A1 (0.53) MAPK1ALDH1A1NPC1RAB9ANOTUM
SCHEMBL10602166 0.82 ALDH1A1 (0.72) MAPK1ALDH1A1NPC1RAB9ANOTUM
SCHEMBL13656064 0.82 ALDH1A1 (0.72) MAPK1ALDH1A1NPC1RAB9ANOTUM
SCHEMBL6796266 0.82 MAPK1 (0.73) MAPK1ALDH1A1NPC1RAB9ANOTUM
SCHEMBL6796268 0.82 MAPK1 (0.73) MAPK1ALDH1A1NPC1RAB9ANOTUM
SCHEMBL22818979 0.81 MAPK1 (0.64) MAPK1ALDH1A1NPC1RAB9ANOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 MAPK1 1684/4885ALDH1A1 905/4885NPC1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.